Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021
SAN CARLOS, Calif., April 9, 2021 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021, to be held virtually April 10-15, 2021. Details are as follows: Title of Presentation: APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression (Abstract ID LB175) Title of Presentation: Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor (Abstract ID LB177) The posters will be available on the e-poster website from at 8:30 am EDT on April 10, 2021, through June 21, 2021. About Apexigen Investor Contact: Apexigen Contact: View original content to download multimedia:http://www.prnewswire.com/news-releases/apexigen-announces-presentations-of-preclinical-data-for-its-tnfr2-antagonist-apx601-and-sirp-antagonist-apx701-programs-at-the-aacr-annual-meeting-2021-301265619.html SOURCE Apexigen, Inc. |